New Developments in the Medical Management of Prostate Cancer

Overview

Journal Mayo Clin Proc

Specialty General Medicine

Date 2010 Jan 1

PMID 20042563

Citations 38

Authors

Manish Kohli

Donald J Tindall

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is a substantial public health burden and a leading cause of cancer-related morbidity and mortality in the United States despite the observation that annual prostate cancer-specific mortality rates have been declining during the previous decade. Although the reasons for this positive development are unclear, a combination of factors may have contributed. This update will review ongoing developments and summarize therapeutic advances in prostate cancer treatment on the basis of the current understanding of prostate cancer biology. Literature for this review was selected in 2009 by searching PubMed for the following keywords: prostatic neoplasms, castration, androgen receptor, hormonal, and chemotherapy. Emphasis is placed on published clinical studies in advanced prostate cancer therapeutics in the past 5 to 10 years. Also included in the review are novel hormonal agents targeting the androgen receptor currently in development for the treatment of advanced prostate cancer.

Citing Articles

Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome.

Yadav S, Hart S, Hu C, Hillman D, Lee K, Gnanaolivu R JCO Precis Oncol. 2020; 3.

PMID: 32923857 PMC: 7446380. DOI: 10.1200/PO.19.00067.

Challenges and Opportunities in Clinical Applications of Blood-Based Proteomics in Cancer.

Bhawal R, Oberg A, Zhang S, Kohli M Cancers (Basel). 2020; 12(9).

PMID: 32867043 PMC: 7564506. DOI: 10.3390/cancers12092428.

[Citron Rho-interacting serine/threonine kinase knockdown suppresses prostate cancer cell proliferation and metastasis by blocking Hippo-YAP pathway].

Haiping C, Qi X, Dawei L, Qiang W Nan Fang Yi Ke Da Xue Xue Bao. 2019; 39(3):257-263.

PMID: 31068310 PMC: 6765676. DOI: 10.12122/j.issn.1673-4254.2019.03.01.

Interplay Between SOX9, Wnt/β-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer.

Khurana N, Sikka S Int J Mol Sci. 2019; 20(9).

PMID: 31027362 PMC: 6540097. DOI: 10.3390/ijms20092066.

Cell division cycle 20 (CDC20) drives prostate cancer progression via stabilization of β-catenin in cancer stem-like cells.

Zhang Q, Huang H, Liu A, Li J, Liu C, Sun B EBioMedicine. 2019; 42:397-407.

PMID: 30904606 PMC: 6491421. DOI: 10.1016/j.ebiom.2019.03.032.

References

Arnold J, Isaacs J . Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer. 2002; 9(1):61-73. PMC: 4124629. DOI: 10.1677/erc.0.0090061. View

Guise T, Mohammad K . Endothelins in bone cancer metastases. Cancer Treat Res. 2004; 118:197-212. DOI: 10.1007/978-1-4419-9129-4_9. View

McMenamin M, Soung P, Perera S, Kaplan I, Loda M, Sellers W . Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999; 59(17):4291-6. View

Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13):1310-9. PMC: 2944770. DOI: 10.1056/NEJMoa0810696. View

Small E, Schellhammer P, Higano C, Redfern C, Nemunaitis J, Valone F . Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24(19):3089-94. DOI: 10.1200/JCO.2005.04.5252. View

Small E, Tchekmedyian N, Rini B, Fong L, Lowy I, Allison J . A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007; 13(6):1810-5. DOI: 10.1158/1078-0432.CCR-06-2318. View

Dehm S, Tindall D . Molecular regulation of androgen action in prostate cancer. J Cell Biochem. 2006; 99(2):333-44. DOI: 10.1002/jcb.20794. View

Iczkowski K, Qiu J, Qian J, Somerville M, Rittmaster R, Andriole G . The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology. 2005; 65(1):76-82. DOI: 10.1016/j.urology.2004.08.042. View

Papandreou C, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S . Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med. 1998; 4(1):50-7. DOI: 10.1038/nm0198-050. View

10.

. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol. 1997; 79(2):235-46. DOI: 10.1046/j.1464-410x.1997.d01-6840.x. View

11.

Kaushal V, Mukunyadzi P, Dennis R, Siegel E, Johnson D, Kohli M . Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. Clin Cancer Res. 2005; 11(2 Pt 1):584-93. View

12.

Kantoff P, Halabi S, Conaway M, Picus J, Kirshner J, Hars V . Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999; 17(8):2506-13. DOI: 10.1200/JCO.1999.17.8.2506. View

13.

Small E, Roach 3rd M . Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response. Semin Oncol. 2002; 29(3):264-73. DOI: 10.1053/sonc.2002.32902. View

14.

Schroder F, Hugosson J, Roobol M, Tammela T, Ciatto S, Nelen V . Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360(13):1320-8. DOI: 10.1056/NEJMoa0810084. View

15.

King J, Xu J, Wongvipat J, Hieronymus H, Carver B, Leung D . Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet. 2009; 41(5):524-6. PMC: 2898503. DOI: 10.1038/ng.371. View

16.

Sternberg C, Whelan P, Hetherington J, Paluchowska B, Slee P, Vekemans K . Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology. 2005; 68(1):2-9. DOI: 10.1159/000084201. View

17.

Huggins C, Hodges C . Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002; 168(1):9-12. DOI: 10.1016/s0022-5347(05)64820-3. View

18.

Klotz L . Hormone therapy for patients with prostate carcinoma. Cancer. 2000; 88(12 Suppl):3009-14. DOI: 10.1002/1097-0142(20000615)88:12+<3009::aid-cncr17>3.3.co;2-5. View

19.

Beer T, Ryan C, Venner P, Petrylak D, Chatta G, Ruether J . Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol. 2007; 25(6):669-74. DOI: 10.1200/JCO.2006.06.8197. View

20.

Gudmundsson J, Sulem P, Manolescu A, Amundadottir L, Gudbjartsson D, Helgason A . Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet. 2007; 39(5):631-7. DOI: 10.1038/ng1999. View